
Adalimumab (Humira) for moderate to severe psoriatic arthritis - horizon scanning review
NHSC

Record Status

This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

NHSC. Adalimumab (Humira) for moderate to severe psoriatic arthritis - horizon scanning review. Birmingham: National Horizon Scanning Centre (NHSC). 2004

Authors' objectives

This study aims to summarise the currently available evidence on adalimumab (Humira) for moderate to severe psoriatic arthritis.

Authors' conclusions

Adalimumab (Humira) is a fully human anti-TNF- α monoclonal antibody in phase III trials for reducing the signs and symptoms of active psoriatic arthritis (PsA) in adults. It is anticipated that adalimumab will be administered by subcutaneous injection once a fortnight at a dose of 40mg. There are currently no published abstracts or results of clinical trials in psoriatic arthritis. Adalimumab is currently licensed for use in rheumatoid arthritis, and is in phase III trials for juvenile idiopathic arthritis, ankylosing spondylitis, chronic-plaque psoriasis and Crohns disease.

Timeliness warning

Available on request from NHSC.

Final publication URL

<http://www.psy-flow.com/sites/psy-flow/files/docs/flow.pdf>

Indexing Status

Subject indexing assigned by CRD

MeSH

Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Psoriatic /drug therapy; Tumor Necrosis Factor- α

Language Published

English

Country of organisation

England

English summary

An English language summary is available.

Address for correspondence

Department of Public Health&Epidemiology, The University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom. Tel: +44 121 414 7831; Fax: +44 121 414 2269; Email: c.packer@bham.ac.uk

AccessionNumber

32004000895

Date bibliographic record published

10/12/2004

Date abstract record published

10/12/2004